S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
Fertil Steril. 2010 Jul;94(2):464-71. doi: 10.1016/j.fertnstert.2009.03.083. Epub 2009 May 13.
To evaluate postoperative long-term cyclic and continuous administration of combined oral contraceptive (OC) pills in preventing endometriosis-related pain recurrence.
Prospective, randomized, controlled trial.
Tertiary care university hospital.
PATIENT(S): Three hundred eleven women who underwent laparoscopic excision for symptomatic ovarian endometrioma.
INTERVENTION(S): Patients were randomly divided into three groups: nonuser group receiving no therapy, and cyclic user group and continuous user group receiving low-dose, monophasic OC pills for 24 months in either cyclic or continuous administration.
MAIN OUTCOME MEASURE(S): Presence and intensity of dysmenorrhea, dyspareunia, and chronic pelvic pain were assessed by a 10-point visual analogue scale (VAS) at 6, 12, 18, and 24 months postoperatively.
RESULT(S): A significant reduction in recurrence rate and VAS scores for dysmenorrhea was evident in the continuous users versus the other groups at 6 months, and in cyclic users versus nonusers at 18 months postoperatively. No significant differences in recurrence rate and VAS scores for dyspareunia and chronic pelvic pain were demonstrated among the groups. The increase of VAS scores from 6-24 months during the study period for dysmenorrhea, dyspareunia, and chronic pelvic pain was significantly higher in nonusers than in the other groups.
CONCLUSION(S): Long-term postoperative use of OC pills can reduce the frequency and the severity of recurrent endometriosis-related dysmenorrhea.
评估术后长期周期性和连续性服用复方口服避孕药(OC)预防子宫内膜异位症相关疼痛复发的效果。
前瞻性、随机、对照试验。
三级保健大学医院。
311 名因症状性卵巢子宫内膜异位症而行腹腔镜切除手术的女性患者。
患者被随机分为三组:非使用者组不接受任何治疗,周期性使用者组和连续性使用者组接受低剂量、单相 OC 避孕药,分别采用周期性或连续性方式服用 24 个月。
术后 6、12、18 和 24 个月时,通过 10 分制视觉模拟评分(VAS)评估痛经、性交痛和慢性盆腔痛的存在和严重程度。
与其他两组相比,连续使用者在术后 6 个月时,复发率和痛经 VAS 评分显著降低,而周期性使用者在术后 18 个月时,复发率和痛经 VAS 评分也显著降低。在性交痛和慢性盆腔痛的复发率和 VAS 评分方面,三组之间无显著差异。在研究期间,从术后 6 个月到 24 个月,痛经、性交痛和慢性盆腔痛的 VAS 评分增加,非使用者显著高于其他两组。
术后长期使用 OC 避孕药可降低复发性子宫内膜异位症相关痛经的频率和严重程度。